Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





PhIICemiplimabW/ChemoVsCemiplimabW/Chemo+OthCaTxPtsW/ResectNonSmalCelLungCa

Cancer
Misako Nagasaka
A Randomized Phase II Platform Study to Evaluate Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for the Perioperative Treatment of Patients with Resectable Non-Small Cell Lung Cancer
Lung

Study Description

This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned.

The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug.

The study is also looking at several other research questions, including:

What are the side effects associated with the investigational treatments in comparison to the control treatment?

Do the investigational treatments or the control treatment have an effect on the type of surgery that is performed?

How much of the study drug(s) are in the blood at a given time?

Does the body make antibodies against the study drugs (which could make the drugs less effective or could lead to side effects)?

Eligibility

Histologically confirmed stage II through IIIB (N2) NSCLC, that is considered resectable with curative intent, as described in the protocol

Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1

Available formalin-fixed paraffin-embedded (FFPE) tumor sample blocks for submission, as described in the protocol

Eastern Cooperative Oncology Group Performance Status scale (ECOG PS) of 0 to 1

Adequate organ and bone marrow function, as described in the protocol

General Key

Any systemic anti-cancer therapy or radiotherapy for the current tumor, as described in the protocol

Presence of known oncogenic alterations in epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) in the tumor prior to randomization, as described in the protocol

Presence of >/= grade 2 peripheral neuropathy

Another malignancy that is progressing or requires active treatment, as described in the protocol

Arm Specific Exclusion Criteria:

Arm 1:

Grade >/= 3 hypercalcemia, as defined in the protocol

Any central nervous system (CNS) pathology that could increase the risk of immune effector cell-associated neurotoxicity syndrome (ICANS), as described in the protocol

Has marked baseline prolongation of the time from the start of the Q wave to the end of the T wave in electrocardiogram(QT)/corrected QT interval (QTc) interval or risk factors for prolonged QTc, as described in the protocol

Note: Other protocol-defined Inclusion/Exclusion criteria apply.

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.